Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 185Neoplasms 111Breast Neoplasms 100Colorectal Neoplasms 90Ovarian Neoplasms 72Neoplasm Metastasis 70Prostatic Neoplasms 67Multiple Myeloma 63Lung Neoplasms 59Squamous Cell Carcinoma of Head and Neck 47Endometrial Neoplasms 46Recurrence 45Pancreatic Neoplasms 43Leukemia, Lymphocytic, Chronic, B-Cell 38Small Cell Lung Carcinoma 37Stomach Neoplasms 36Carcinoma, Renal Cell 36Melanoma 33Leukemia, Myeloid, Acute 32Urinary Bladder Neoplasms 28Triple Negative Breast Neoplasms 28Lymphoma, Non-Hodgkin 27Parkinson Disease 4, Autosomal Dominant Lewy Body 26Head and Neck Neoplasms 25Lymphoma, Follicular 24Carcinoma, Hepatocellular 24Lymphoma, Large B-Cell, Diffuse 23Esophageal Neoplasms 22Advanced Solid Tumors 22Lymphoma 21

Interventions

sugemalimab 1pegaspargase 1Oxaliplatin 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Extranodal NK-T-Cell × 30 days × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡